Navigation Links
AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
Date:9/9/2011

ng mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the second half of 2011 under a grant from the US Army Medical Research and Material Command.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
2. AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results
3. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
4. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
5. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
6. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
8. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
9. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
10. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
11. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 ... Devices Market by Type (Dermatology Treatment Devices, and Dermatology ... Microscopes]), by Application, by Geography - Analysis and Forecast ... to reach $11.88 billion by 2019, at a CAGR ... through the TOC of Global Dermatology Devices Market for ...
(Date:7/28/2015)... 2015 Transparency Market Research (TMR) has ... Cancer Diagnostics Market - Global Industry Analysis, Size, Share, ... According to this report, the global cancer diagnostics market is ... forecast period of 2014 to 2020. In 2013, the global ... expected to be worth US$168,649.3 million by 2020.The increasing prevalence ...
(Date:7/28/2015)... WESTFORD, Mass., July 28, 2015   Cynosure, ... manufactures and markets medical devices for aesthetic procedures ... results for the three months ended June 30, ... another quarter of double-digit growth, as revenues increased ... said Cynosure Chief Executive Officer Michael Davin. "While ...
Breaking Medicine Technology:Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 2Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 3Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 3Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 4Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 2Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 3Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 4Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 5Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 6Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 7Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 8Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 9Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 10Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 11Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 12Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 13
... Encouraging and Support Phase III Study, DEERFIELD, ... BAX ) and The Alzheimer,s Disease Cooperative Study ... multi-center U.S. Phase III study,evaluating the role of ... immunoglobulin preparation, for the,treatment of patients with mild ...
... 28 CuraGen Corporation,(Nasdaq: CRGN ) and ... initiation of patient dosing in a Phase I/II ... in combination with the anthracycline idarubicin for the,treatment ... being conducted at,multiple sites in the European Union. ...
Cached Medicine Technology:Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 2Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 3Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 4Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 5Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 6CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 2CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 3CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 4CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 5CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 6
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... Mindful Her, ... all ages to take their healthy and mindful living practices to the next level, ... and author of Living with Intent as keynote. Global Girls, an Orange County ...
(Date:7/28/2015)... New Port Richey, FL (PRWEB) , ... July ... ... from Brown University and The Miriam Hospital examines outcomes for inmates who continued ... and found the latter group was more likely to relapse to opiate use ...
(Date:7/28/2015)... ... 2015 , ... Darryl Worley’s Annual Tennessee River Run events ... of raising money for the Darryl Worley Foundation. Worley will host Wade Hayes, ... Saturday, Oct. 3. , This year’s concert will have a second stage showcasing ...
(Date:7/28/2015)... ... July 28, 2015 , ... By 2016, the number of smartphones worldwide will ... customers on a highly personal basis, increasing customer loyalty. However, capitalizing on this is ... or lose customers to more nimble competitors. , The Open Mobile Summit 2015 is ...
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Edward Buckingham ... of Dr. Sudeep Roy in July 2016. Coming to Austin from Philadelphia, Dr. ... Buckingham. The twelve-month long training is facilitated annually by the American Academy of ...
Breaking Medicine News(10 mins):Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 2Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 3Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 2Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 3Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 4Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 2Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 3Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 3Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3
... Individual Corporate Criminal Fine in History;Civil Settlement Up To ... Lilly and Company today agreed to plead guilty and ... uses not approved by the Food and Drug Administration ... This resolution includes a criminal fine of $515 million, ...
... Peptimmune, Inc. ("Peptimmune"), a privately held ... (NYSE: NVS ) an exclusive option to ... Peptimmune,s multiple sclerosis drug candidate. In a separate but ... L.P. made an equity investment in Peptimmune.In the event ...
... Adverse prescription-drug reactions,cost the United States healthcare ... and Drug Administration, and put numerous patients at ... , In a major ... (UH) in Cleveland has launched a state-of-the-art physicians,computer ...
... 2009 Paintballs can cause severe and ,visually ... settings without proper eye protection, reports a study ... Journal of Ophthalmology (www.AJO.com), published by Elsevier. ... cause tremendous damage to vital ocular structures often ...
... 15, 2009) Tufts University has received a grant ... design an obesity prevention program for new immigrants. ... the clinical trial will randomize more than 400 ... in Somerville, Mass., and follow them for two ...
... and national governments currently debating proposals to raise alcohol ... the February edition of Addiction journal finds ... people are to drink. And when they do drink, ... four decades, researchers documented a concrete association between the ...
Cached Medicine News:Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 2Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 3Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 4Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 5Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 6Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 7Health News:Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis 2Health News:University Hospitals and OnCallData Launch New Portal Combining State-of-the- Art Electronic Prescribing and Medication Reconciliation 2Health News:University Hospitals and OnCallData Launch New Portal Combining State-of-the- Art Electronic Prescribing and Medication Reconciliation 3Health News:Paintballs can cause 'devastating' eye injuries 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 3Health News:Alcohol taxes have clear effect on drinking 2
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Controls for APC Resistance / Factor V Leiden Functional Assay...
Pefakit PiCT LMWH Calibrators...
PT-HS with Calcium - 2 ml...
Medicine Products: